A senior Trump administration official and key adviser are slamming OpenAI head of strategic futures Dean Ball's views on regulation, casting a shadow on the future of the company's relationship with the government. Why it matters: The criticism targets a former White House architect of the administration's AI Action Plan who now works at OpenAI, potentially complicating the company's relationship with the Trump administration. State of play: The Trump administration is grappling with how to balance competition and cybersecurity concerns as increasingly capable Chinese AI models come onto the scene. - Ball said the Trump administration would eventually land on creating regulatory risk around using Chinese models as "their best…
With President Trump in attendance, an all-superstar lineup that included Madonna, BTS, Justin Bieber and Burna Boy felt a little more political than it might have otherwise.
Several high-profile Trump administration nominees face committee votes in the coming weeks that will show whether outgoing GOP senators are willing to buck the administration — or at least exert some leverage. Centers for Disease Control and Prevention (CDC) director nominee Erica Schwartz and attorney general nominee Todd Blanche received a tepid reception at their [...]
“Due to heightened tensions in the Middle East, the security environment remains complex with the potential for unforeseen escalation,” the State Department wrote in a Saturday statement.
By Andrea Widburg A provocative essay from Lee Smith makes the case that Vance, having been humiliated over Iran, is finding scapegoats, including Israel and Trump himself.
Promising, inexpensive generic drugs may never receive large-scale testing as anti-aging treatments—not because the science is weak, but because the pharmaceutical regulatory system rewards patentable products over affordable public-health solutions. Metformin and rapamycin have shown potential in animal research to influence aging-related biological processes. Yet definitive human trials remain limited. The central obstacle is financial: […] The post Big Pharma Will Never Help the People appeared first on StoneZone .
Promising, inexpensive generic drugs may never receive large-scale testing as anti-aging treatments—not because the science is weak, but because the pharmaceutical regulatory system rewards patentable products over affordable public-health solutions. Metformin and rapamycin have shown potential in animal research to influence aging-related biological processes. Yet definitive human trials remain limited. The central obstacle is financial: rigorous Phase 3 trials can cost hundreds of millions of dollars, while manufacturers have little incentive to fund studies of off-patent drugs that competitors could immediately sell at low prices. That market failure becomes a regulatory failure when government agencies rely primarily on…Open